TNFRSF17 and Miyoshi myopathy: Our previous study showed that combined infusion of humanized anti-CD19 and anti-BCMA CAR T cells achieved 92% ORR in 62R/R MM patients, and 60% of patients achieved CR or better, which is consistent with previous BCMA CAR T cell results20.